SOM Faculty Profile : Mark E Shirtliff

Mark E Shirtliff

Mark E Shirtliff Ph.D.

Academic Title: Associate Professor

Primary Appointment: Baltimore College of Dental Surgery/Dental School

Secondary Appointments: Microbiology and Immunology

mshirtliff@umaryland.edu

Location: UMB Dental School, 9209 (office); 9414 (lab)

Phone: (410) 706-2263

Fax: (410) 706-0865

Personal History

EDUCATION

January 2001: Ph.D. in Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, USA
Dissertation Title, “Staphylococcus aureus: Roles in Osteomyelitis”
Advisor: Dr. JT Mader

May 1993: B.S. (Cum Laude Honors) , University of Houston - Clear Lake, Houston, TX, USA , Junior and Senior Years
Major: Biology; Minor: Geography (University of Alberta, Edmonton, AB, Canada , Freshman and Sophomore Years; Major: Biology; Minor: Geography)

Research Interests

Differential gene expression and protein production using genomic and proteomic techniques, biofilms, animal models of infection (osteomyelitis, implant infection, abscess, and endophthalmitis), identification of vaccine candidates and antimicrobial targets, host-pathogen interactions.

Grant Support:

“Staphylococcus aureus biofilms: in vitro and in vivo studies” National Institutes of Health – R01-AI069568-02. PI – Mark E. Shirtliff. $1,250,000 (+ $606,250 Indirects). June 1, 2007 – May 31, 2012.

“Vaccine development for recurrent musculoskeletal infections” Department of Defense. – W81XWH-07-1-0210. PI – ME Shirtliff. $280,000 (+ $70,000 Indirects). Sept 1, 2008 – Aug 31, 2010.

“Determination of differential gene expression in Staphylococcus aureus biofilms through microarray analysis.” National Institutes of Health. PI – ME Shirtliff. $200,000 in material costs only – no indirects provided. June 1, 2006 – present.

“Determination of differential gene expression in Candida Albicans biofilms through microarray analysis.” National Institutes of Health. PI – ME Shirtliff. $200,000 in material costs only – no indirects provided. June 1, 2006 – present.

“Identification of determinants essential for biofilm formation and virulence in methicillin-resistant Staphylococcus aureus (MRSA) using a global genetic approach” PI – ME Shirtliff and KS McIver. University of Maryland, College Park. $75,000. Submitted June 15, 2008.

Publications

Shirtliff ME and Leid JG, Editors. Biofilms and Device-Related Infections. Springer, New York, NY. 2008. – in press.

Brady RA, O’May GA, Leid JG, Costerton JW, and Shirtliff ME. Resolution of Staphylococcus aureus biofilm infection using vaccination and antibiotic treatment. Science. 2008. – submitted.

Costerton JW, Veeh R, Shirtliff ME, Pasmore M, Post C, and Ehlich G. The application of biofilm science to the study and control of chronic bacterial infections. In: Science in Medicine: The JCI Textbook of Molecular Medicine. ed Marks AR. American Society for Clinical Investigation. Jones and Bartlett, Boston, MA. 2008. – in press.

Brady RA, Calhoun JH, and Shirtliff ME. Infections of orthopaedic implants and devices. In: Biofilms and Device-Related Infections. Springer, New York, NY. ed. Shirtliff ME. 2008. – in press.

O’May G, Jacobsen SM, Shirtliff ME, and Mobley H. Catheter-related urinary tract infections. In: Biofilms and Device-Related Infections. Springer, New York, NY. ed. Shirtliff ME. 2008. – in press.

Calhoun JH, Manning M, and Shirtliff ME. Long bone osteomyelitis. Sem. Plastic Surg. 2008. – in press.

Scheper MA, Shirtliff ME, Meiller TF, Peters B, and Jabra-Rizk MA. Farnesol, a fungal quorum sensing molecule, triggers apoptosis in human oral squamous carcinoma cells. Neoplasia. 2008. – in press.

Fux CA, Stoodley P, Shirtliff ME, and Costerton JW. Biofilms. In: Antimicrobial Drug Resistance: Principles and Practice for the Clinic and Bench. ed Mayers DL. Infectious Disease Series. ed Georgiev VS. Humana Press. March, 2008.

Jacobsen SM, Lane MC, Harro JM, Shirtliff ME*, and Mobley HLT*. *Both authors contributed equally. The high-affinity phosphate transporter Pst is a virulence factor for Proteus mirabilis during complicated urinary tract infection. FEMS Immun Med Micro. 52(2):180-93, 2008.

Jacobsen SM, Stickler D, Mobley HLT, and Shirtliff ME. The role of Escherichia coli and Proteus mirabilis in catheter-related urinary tract infections. Clin Micro Rev. 21(1):26-59, 2008.

Brady R, Leid JG, Calhoun JH, and Shirtliff ME. Osteomyelitis and the role of biofilms in chronic infection. FEMS Immun Med Micro. 52:13-22, 2008.

Calhoun JH, Sexton DJ, and Shirtliff ME. Hematogenous osteomyelitis in adults. In: Infectious Diseases. Up To Date Publishing Corporation. Wellesley, MA. 2007.

Brady RA, Leid JG, Kofonow J, Costerton JW, and Shirtliff ME. Immunoglobulins to surface-associated biofilm immunogens provide a novel means of visualization of methicillin-resistant Staphylococcus aureus biofilms. Appl Env Micro. 73(20): 6612-9, 2007

Calhoun J, Christensen G, Brady RA, Shirtliff ME. Osteomyelitis. In: Expert Guide to Infectious Diseases. ed. Tan JS. American College of Physicians-American Society of Internal Medicine. Philadelphia, PA. 2007.

Lazzarini L, Overgaard KA, Conti E, and Shirtliff ME. Experimental osteomyelitis: what have we learned from animal studies about the systemic treatment of osteomyelitis? J. Chemother. 2006.

abra-Rizk MA, Shirtliff ME, and Meiller T. Farnesol effect on Candida albicans and Candida dubliensis. FEMS Yeast Research. 2006.

Brady R, Leid JG, Calhoun JH, and Shirtliff ME. Osteomyelitis. FEMS Medical Micro Immun. 2006.

Calhoun J, Christensen G, Brady RA, Shirtliff ME. Osteomyelitis. Expert Guide to Infectious Diseases. ed. Tan JS. American College of Physicians-American Society of Internal Medicine. Philadelphia, PA. 2006.

Leid JG, Costerton JW, Calhoun JH, and Shirtliff ME. Acute septic arthritis. FEMS Medical Micro Immun. 2006.

Brady RA, Leid JG, Costerton JW, and Shirtliff ME. Identification of Staphylococcus aureus proteins recognized by the antibody mediated immune response to a biofilm infection. Infect. Immun. 74(6): 3415-3426, 2006.

Jabra-Rizk MA, Meiller T, James CE, and Shirtliff ME. Effect of farnesol on Staphylococcus aureus biofilm formation and antimicrobial susceptibility. Antimicrob Agents Chemother. 50(4):1463-9 2006.

Brady RA, Leid JG, Costerton JW, and Shirtliff ME. Osteomyelitis. Clin. Micro. News. 28(9): 65-72, 2006.

Leid JG, Carey JW, Shirtliff ME, Hassett DJ, Parsek MR, and Jeffers AK. The exopolysaccharide alginate protects Pseudomonas aeruginosa biofilm bacteria from IFN-gamma-mediated macrophage killing. J. Imm. 175(11):7512-8, 2005.

Shirtliff ME, Bargmeyer A, and Camper AK. Assessment of the bioelectric effect to eliminate mixed-species biofilms. Appl Environ Micro.71(10): 2005.

Fux CA, Shirtliff ME, Stoodley P, and Costerton JW. Can laboratory strains mirror "real world" pathogenesis? Trends Micro. 13(2):2005.

Shirtliff ME, Cripps MW, and Calhoun JH. Staging Systems for Long Bone Osteomyelitis. In: Infectious Diseases. Up To Date Publishing Corporation. Wellesley, MA. 2005.

Shirtliff ME, Cripps MW, and Calhoun JH. Cierny-Mader Staging and the Treatment of Long Bone Osteomyelitis. In: Infectious Diseases. Up To Date Publishing Corporation. Wellesley, MA. 2005.

Veeh RH, Shirtliff ME, Petik JR, Flood JA, Davis CC, Seymour JL, Hannsmen MA, Kerr KM, Costerton JW, and Pasmore, M. Detection of Staphylococcus aureus Biofilm on Tampons and Menses. J Infect Dis. 188(4):519-530, 2003.

Shirtliff ME and Mader JT. Imaging in osteomyelitis. Curr Treat Options Infect Dis 5(4):323-335, 2003.

Worley SD, Li F, Wu R, Wei C-I, Williams JF, Owens J, Wander JD, Bargmeyer AM, and Shirtliff ME. A novel N-halamine monomer for preparing biocidal polyurethane coatings. Surface Coatings Int. Part B: Coat. Trans. 86(B4): 273-277, 2003.

Costerton JW, Stoodley P, Shirtliff ME, Pasmore M, Cook G. Biofilms, Biomaterials, and device-related infections. In: Biomaterials Science: An Introduction to Materials in Medicine. ed. Ratner BD, Hoffman AS, Schoen FJ, and Lemons JE. 2003.

Costerton JW, Veeh R, Shirtliff ME, Pasmore M, Post C, and Ehrlich G. The application of biofilm science to the study and control of chronic bacterial infections. J Clin Invest. 112(10):1466-1477, 2003.

Shirtliff ME, Calhoun JH, and Mader JT. Evaluation of gatifloxacin in the treatment of methicillin sensitive Staphylococcus aureus osteomyelitis in a rabbit model. Antimicrob Agents Chemother. 46(1):231-233, 2002.

Mader JT, Wang J, Shirtliff ME, and Calhoun J. Osteomyelitis. Expert Guide to Infectious Diseases. ed. Tan JS. American College of Physicians-American Society of Internal Medicine. Philadelphia, PA. 585-604, 2002.

Mader JT and Shirtliff ME. Osteomyelitis. In: Conn's Current Therapy, 2002 Edition. ed. Rakel RE and Bope ET. WB Saunders Co. Philadelphia, PA. 1010-1016, 2002.

Shirtliff ME, Calhoun JH, and Mader JT. Experimental osteomyelitis treatment with antibiotic-impregnated hydroxyapatite. Clin Orth Related Res. 401:239-247, 2002.

Leid JG, Costerton JW, Shirtliff ME, Gilmore MS, and Engelbert M. Immunology of staphylococcal biofilm infections in the eye: New tools to study endophthalmitis. J DNA Cell Biol. 21(5):405-413, 2002.

Shirtliff ME and Lefrock J. Septic Arthritis. In: Musculoskeletal Infections. ed.Mader JT and Calhoun JH. Marcel Dekker, Inc. New York, NY. 183-209, 2002.

Leid JG, Shirtliff ME, Costerton JW, and Stoodley P. Human leukocytes adhere to, penetrate, and respond to Staphylococcus aureus biofilms. Infect Immun. 70(11):6339-6345, 2002.

Shirtliff ME, Leid J, and Costerton JW. Basic science of musculoskeletal infections. In: Musculoskeletal Infections. ed. Mader JT and Calhoun JH. Marcel Dekker, Inc. New York, NY. 1-61, 2002.

Faculty members: Click here to update your contact information and create a profile.